Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H35NO5.ClH |
Molecular Weight | 466.01 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2
InChI
InChIKey=PLGQWYOULXPJRE-UHFFFAOYSA-N
InChI=1S/C25H35NO5.ClH/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5;/h9-14,18-19H,6-8,15-17H2,1-5H3;1H
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Curator's Comment: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Alpha-1 adrenergic receptor (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2442008 |
|||
Target ID: Muscarinic acetylcholine receptors (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2442008 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Colofac Approved UseColofac is used to treat symptoms of irritable bowel syndrome and similar problems. Launch Date1978 |
|||
Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Launch Date1978 |
|||
Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis Launch Date1978 |
PubMed
Title | Date | PubMed |
---|---|---|
Drug therapy options for patients with irritable bowel syndrome. | 2001 Jul |
|
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS. | 2001 Jul-Aug |
|
Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. | 2002 Jun 20 |
|
On-line micellar electrokinetic chromatography-mass spectrometry: feasibility of direct introduction of non-volatile buffer and surfactant into the electrospray interface. | 2003 Jun 6 |
|
Atmospheric pressure photoionization for enhanced compatibility in on-line micellar electrokinetic chromatography-mass spectrometry. | 2005 Aug 15 |
|
Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. | 2005 Aug 20 |
|
Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine. | 2005 Jan 4 |
|
Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation? | 2006 |
|
Formulation of an antispasmodic drug as a topical local anesthetic. | 2006 Dec 1 |
|
A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma. | 2006 Feb |
|
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. | 2006 May |
|
"My patients are the sickest". | 2006 May |
|
Colon-specific drug delivery for mebeverine hydrochloride. | 2007 Dec |
|
[Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome]. | 2008 |
|
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. | 2008 Apr |
|
Serotonin receptor modulators in the treatment of irritable bowel syndrome. | 2008 Feb |
|
Evaluation of the Birmingham IBS symptom questionnaire. | 2008 Jul 23 |
|
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange. | 2008 Mar |
|
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. | 2008 May |
|
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008 Nov 13 |
|
Drug use in children: cohort study in three European countries. | 2008 Nov 24 |
|
Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine. | 2009 |
|
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis]. | 2009 |
|
[How to raise efficacy of gastroesophageal reflux disease treatment]. | 2009 |
|
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality. | 2009 |
|
[A method for non-medicamentous treatment of irritated bowel syndrome]. | 2009 May-Jun |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Validated HPLC determination of the two fixed dose combinations (chlordiazepoxide hydrochloride and mebeverine hydrochloride; carvedilol and hydrochlorothiazide) in their tablets. | 2010 Jul-Aug |
|
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). | 2010 Nov 18 |
|
Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream. | 2010 Nov 4 |
|
Autoimmune hepatitis triggered by nitrofurantoin: a case series. | 2010 Sep 23 |
|
Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports. | 2010 Sep 6 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicines.org.uk/emc/PIL.22522.latest.pdf
One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2444442
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C73596
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
C005096
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
235827
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
220-400-0
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
2753-45-9
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
m7108
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
15VZ5AL4JN
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
SUB03102MIG
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL282121
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
17683
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
DTXSID1045372
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
169101
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
100000086181
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD